Mizuho raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $13 from $11 and keeps an Outperform rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Corvus Pharmaceuticals’ Soquelitinib Study: A Potential Game-Changer for Atopic Dermatitis
- Corvus Pharmaceuticals’ Phase 3 Study on Soquelitinib: A Potential Game-Changer in Lymphoma Treatment
- Corvus Pharmaceuticals initiated with an Overweight at Barclays
- Corvus Pharmaceuticals Appoints David Moore as Director